

09/856391

copy

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No. 19452A-000320US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On December 7, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: Mark T. Davis

Mark T. Davis

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jamey D. Marth et al.

Patent No.: 7,256,171 B1

Filed: January 7, 2002

For: USE OF CORE 2 GLcNAc  
TRANSFERASE INHIBITORS IN  
TREATING INFLAMMATION

Examiner: Zara, Jane J.

Art Unit: 1635

REQUEST FOR CERTIFICATE OF  
CORRECTION

**Certificate**

DEC 13 2007

**of Correction**

Sir:

Pursuant to 37 CFR 1.322, Applicant submits a Request for Certificate of Correction correcting an error in the title of the patent made at the time of printing. Priority is claimed to PCT Pub. No. WO00/31109 and a copy of its face sheet is enclosed to evidence the correct title. No fee is required for this Certificate. The desired correction is set forth on form PTO 1050, enclosed.

Respectfully submitted,

Kevin L. Bastian  
Kevin L. Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
(415) 576-0200  
Fax (415) 576-0300  
KLB:mtl 61227139 v1

DEC 13 2007



(Also Form PTO-1050)

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

**PATENT NO.** : 7,256,171 B1  
**DATED** : August 14, 2007  
**INVENTOR(S)** : Jamey D. Marth et al.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the face sheet under (54) title please change:

"USE OF CORE 2 G1CNAC TRANSFERASE INHIBITORS IN TREATING INFLAMMATION"  
to -- USE OF CORE 2 GlcNAc TRANSFERASE INHIBITORS IN TREATING INFLAMMATION--

**MAILING ADDRESS OF SENDER:**

Kevin L. Bastian, Reg. No. 34,774  
Townsend and Townsend and Crew, LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, CA 94111-3834  
61227160 v1


**PATENT NO. 7,256,171 B1**

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**DEC 13 2007**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No. 19452A-000320US



Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

December 7, 2007

TOWNSEND and TOWNSEND and CREW LLP

By:

Mark T. Davis

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jamey D. Marth et al.

Patent No.: 7,256,171 B1

Filed: January 7, 2002

For: USE OF CORE 2 GLcNAc  
TRANSFERASE INHIBITORS IN  
TREATING INFLAMMATION

Examiner: Zara, Jane J.


Art Unit: 1635

REQUEST FOR CERTIFICATE OF  
CORRECTION

Sir:

Pursuant to 37 CFR 1.322, Applicant submits a Request for Certificate of Correction correcting an error in the title of the patent made at the time of printing. Priority is claimed to PCT Pub. No. WO00/31109 and a copy of its face sheet is enclosed to evidence the correct title. No fee is required for this Certificate. The desired correction is set forth on form PTO 1050, enclosed.

Respectfully submitted,

  
Kevin L. Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
(415) 576-0200  
Fax (415) 576-0300  
KLB:mtd 61227139 v1

DEC 13 2007

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

**PATENT NO.** : 7,256,171 B1  
**DATED** : August 14, 2007  
**INVENTOR(S)** : Jamey D. Marth et al.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the face sheet under (54) title please change:

"USE OF CORE 2 G1CNAC TRANSFERASE INHIBITORS IN TREATING INFLAMMATION"  
to -- USE OF CORE 2 GlcNAc TRANSFERASE INHIBITORS IN TREATING INFLAMMATION--


**MAILING ADDRESS OF SENDER:**

Kevin L. Bastian, Reg. No. 34,774  
Townsend and Townsend and Crew, LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, CA 94111-3834  
61227160 v1

**PATENT NO.** 7,256,171 B1

DEC 13 2007

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |   |
|--|--|---|
| (51) International Patent Classification <sup>6</sup> :<br><b>C07H 21/04, C07K 16/00, C12N 15/63,<br/>15/85, A61K 48/00</b>  |  | (11) International Publication Number:<br><b>WO 00/31109</b>  |
| <b>A1</b>  |  | (43) International Publication Date:<br>2 June 2000 (02.06.00)  |
| <p>(21) International Application Number: PCT/US99/27465</p> <p>(22) International Filing Date: 20 November 1999 (20.11.99)</p> <p>(30) Priority Data:<br/>60/109,416 21 November 1998 (21.11.98) US<br/>60/113,679 21 December 1998 (21.12.98) US</p> <p>(71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): MARTH, Jamey, D. [US/US]; 7190 Shoreline Drive, San Diego, CA 92122 (US). ELLIES, Leslie, G. [US/US]; 3295 Caminito East Bluff #188, La Jolla, CA 92037 (US).</p> <p>(74) Agents: SMITH, Timothy, L. et al.; Townsend and Townsend and Crew LLP, 8th Floor, Two Embarcadero Center, San Francisco, CA 94111-3834 (US).</p> |  | <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b><br/>With international search report.</p> |

(54) Title: USE OF CORE 2 GlcNAc TRANSFERASE INHIBITORS IN TREATING INFLAMMATION

(57) Abstract

This invention provides compounds and methods for treating inflammation. The compounds modulate the core 2 oligosaccharide-mediated binding of inflammatory cells, such as neutrophils, to endothelial cells and other myeloid cells. Significantly, the of the invention methods block inflammation without affecting lymphocyte trafficking. In some embodiments, the compounds inhibit the activity of a core 2 GlcNAc transferase that is involved in synthesizing the core 2 oligosaccharides.

DEC 13 2007